Testing effectiveness (Phase 2)Not Yet RecruitingNCT07392229What this trial is testingZanubritnib and Anti-MAG NeuropathyWho this might be right forAnti-MAG IgM-associated Demyelinating Polyneuropathy Azienda Ospedaliera di Padova 50